Neutrophil gelatinase‐associated lipocalin (NGAL): A new marker of kidney disease

NGAL, the New Marker for Acute Kidney Injury

Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.

BACKGROUND AND OBJECTIVES Chronic kidney disease (CKD) has recently assumed epidemic proportion, becoming a troubling emerging cause of morbidity, especially if it progresses to terminal stage (ESRD). The authors aimed to evaluate whether neutrophil gelatinase-associated lipocalin (NGAL), a novel specific biomarker of acute kidney injury, could predict the progression of CKD. DESIGN, SETTING,...

Value of plasma neutrophil gelatinase-associated lipocalin (NGAL) in distinguishing between acute kidney injury (AKI) and chronic kidney disease (CKD)

OBJECTIVE In this study, we aimed to determine whether plasma NGAL levels could be used as a biomarker for distinguishing between AKI and CKD in emergency medicine. MATERIALS AND METHODS This prospective study was conducted at the ED of a training and research hospital over a six-month period in 2015. Three groups were defined: an AKI group - defined as a new onset of at least a 1.5-fold or ≥...

Kidney Injury Marker 1 and Neutrophil Gelatinase-Associated Lipocalin in Chronic Kidney Disease.

The current categorization of chronic kidney disease (CKD) is based on biomarkers of the glomerular function (estimated glomerular filtration rate, eGFR) and injury (urinary albumin creatinine ratio, UACR) and provides information on the risk of death and of progression of kidney disease. However, there are gaps in knowledge regarding the risk stratification of elderly patients with eGFR 45-60 ...

Clinical usefulness of serial neutrophil geletinaseassociated lipocalin (NGAL) change as a predictor for acute kidney injury

Results Persistent elevation of plasma NGAL above 1000 ng/mL on 0 and 12 hours was significantly associated with need for early renal replacement therapy. Patient with increased level of NGAL at 12 hours showed unfavorable outcome which is related to renal replacement therapy or progressive renal impairment (13/25; 48% of patients). Conversely, 2/17 (11.8%) of patients had poor renal outcome wh...